About REWEAL

Allergy immunotherapy has evolved significantly over the last decade, triggered by the need for more evidence-based medicine. ALK worked with the allergy community to develop the fields’ most robust clinical program, enrolling over 22,000 patients, enabling prescribing decisions to move from experience-based to evidence-based. But ideal-world evidence alone can only tell you so much.

That’s where our REWEAL program comes in. Comprising patient data from independent sources across multiple countries, REWEAL brings physicians best-in-class real-world evidence. It reveals the benefits of AIT for people with allergy – from improvements in QoL and reduced drug burden to disease modification and other long term outcomes.

Our goal is to help inform the right treatment decision by providing you with the best in both clinical and real-world evidence.

REWEAL – Real patients. Real questions. Answered.

Learn more about our REWEAL initiative and how RWE studies and RCTs complement each other